KNX 400
Alternative Names: KNX-400Latest Information Update: 17 Jul 2023
At a glance
- Originator Kinoxis Therapeutics; University of Sydney
- Developer Boehringer Ingelheim; Kinoxis Therapeutics
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Oxytocin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders; Psychiatric disorders
Most Recent Events
- 17 Jul 2023 Early research in Neurological disorders in Australia (unspecified route)
- 17 Jul 2023 Early research in Psychiatric disorders in Australia (unspecified route)
- 05 May 2023 Kinoxis Therapeutics enters into a strategic partnership and licensing agreement with Boehringer Ingelheim to develop oxytocin targeting therapeutics for Neuropsychiatric disorders